UroGen Pharma, Inc. products

The UroGen Pharma Chilling Block supports temperature-controlled chilling with chambers appropriately sized for the vials and syringes needed to prepare JELMYTO.

UGN-301 is UroGen’s in-licensed anti-CTLA-4 antibody (zalifrelimab). UGN-201 is our proprietary formulation of imiquimod, a toll-like receptor 7 (TLR 7) agonist. When combined, these medicines stimulate both the innate (UGN-201) and adaptive (UGN-301) immune responses, both of which are important for fully harnessing the power of the immune system to fight cancer.

RTGel™ reverse-thermal hydrogel technology is transforming medicine delivery in urology When confronted with challenging conditions in urology, too often there’s no right tool for the job. That’s why UroGen has developed RTGel, an innovative technology platform designed to work with anatomical complexity—not against it—and facilitate intracavitary treatment of challenging urological conditions.

A multiuse device, the UroJect12 Syringe Lever enables ease of instillation. JELMYTO is viscous, even when chilled, and must be instilled with the UroJect12 device.

UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy with UGN-201.